WO2001079184A1 - Composes de piperazine substitues - Google Patents
Composes de piperazine substitues Download PDFInfo
- Publication number
- WO2001079184A1 WO2001079184A1 PCT/JP2001/003107 JP0103107W WO0179184A1 WO 2001079184 A1 WO2001079184 A1 WO 2001079184A1 JP 0103107 W JP0103107 W JP 0103107W WO 0179184 A1 WO0179184 A1 WO 0179184A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- group
- unsubstituted
- disease
- prodrug
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a compound having an inhibitory action on poly (ADP-ribose) polymerase (PARP, also known as poly (ADP-ribose) synthetase).
- PARP poly (ADP-ribose) polymerase
- compounds having a PARP inhibitory activity include diseases caused by enhanced PARP activity, such as cerebral ischemic injury (eg, stroke, sequelae after stroke (disorders associated with stroke and sequelae after stroke (eg, exercise)).
- Neurodegenerative diseases eg, Parkinson's disease, Alzheimer's disease, Huntington's chorea, etc.
- brain contusion head trauma, spinal injury, diabetes, ischemic heart disease ( For example, myocardial infarction, angina pectoris, arrhythmia, etc., organ damage due to ischemia or reperfusion of ischemia (eg, myocardial ischemia-reperfusion injury, acute renal failure, renal ischemia, organ transplantation, percutaneous Disorders caused by surgical procedures such as coronary angioplasty, etc., inflammation (eg, arthritis, rheumatoid arthritis, sepsis), inflammatory enteritis (eg, colitis, Crohn's disease) Etc.), cancer, cachexia (force hex), renal disorder, osteoporosis, acute and chronic pain (eg, neurogenic pain), sepsis (eg, endotoxin shock), skeletal muscle degeneration, muscular dystrophy It is useful as a therapeutic
- cerebral ischemic injury In particular, cerebral ischemic injury, stroke, sequelae after stroke, cerebral edema, neurodegenerative disease, Parkinson's disease, Alzheimer's disease, Huntington's chorea, cerebral contusion, head trauma, spinal injury, dysuria, ischemic heart disease It is useful as a remedy for myocardial infarction, myocardial ischemia reperfusion, angina, arrhythmia, arthritis, chronic rheumatoid arthritis, inflammatory bowel disease, sepsis, cancer, skin aging, etc.
- Background art describes myocardial infarction, myocardial ischemia reperfusion, angina, arrhythmia, arthritis, chronic rheumatoid arthritis, inflammatory bowel disease, sepsis, cancer, skin aging, etc.
- Examples of compounds having a poly (ADP-ribose) polymerase inhibitory activity include dihydroisoquinolinone derivatives and isoquinolinone derivatives (for example, described in Anti-cancer Drug Design (1991), 7, 107-117), Nsamide derivatives (for example, international public Open (WO) No. 99/47494), tetracyclic compounds (for example, described in International Publication (WO) No. 99/11645) and the like. (AD P-ribose) Polymerase inhibitory activity has been reported (for example,
- the present inventors have conducted intensive studies in order to achieve the above object, and as a result, have found that the compound represented by the general formula (1) or a prodrug thereof or a pharmaceutically acceptable salt thereof (hereinafter referred to as the compound of the present invention as necessary) (Sometimes abbreviated as abbreviated) Power S Excellent poly (AD P-ribose) polymerase inhibitory activity.
- the compound of the present invention is particularly superior in action as compared with the compound specifically described in the above-mentioned International Publication (W 0) No. 9981624.
- the present invention relates to the following.
- R 7 is a hydrogen atom
- Substituted or unsubstituted alkyl group substituted or unsubstituted alkenyl group, substituted or unsubstituted alkynyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted cycloalkylalkyl group, substituted or unsubstituted A substituted or unsubstituted aromatic group, a substituted or unsubstituted saturated heterocyclic group, or a substituted or unsubstituted acyl group
- R 8 is a substituted or unsubstituted alkyl group, substituted Or an unsubstituted alkenyl group, a substituted or unsubstituted alkyny
- R ⁇ RR 3 and R 4 are each independently a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted cycloalkyl Group, substituted or unsubstituted cycloalkylalkyl group, substituted or unsubstituted arylalkyl group, substituted or unsubstituted aromatic group, substituted or unsubstituted saturated heterocyclic group, substituted or unsubstituted acyl Represents a group, a nitrogen atom, a nitro group, or a group represented by the formula: one OR la , one NR la R lb, or one SR la (R la and R lb are each independently a hydrogen atom or substituted Or an unsubstituted alkyl group).
- R 5 is a substituent on the piperazine ring, which may be absent or one or more, the same or different, and may be a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted Or an unsubstituted alkynyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkylalkyl group, a substituted or unsubstituted arylalkyl group, a substituted or unsubstituted aromatic group, substituted or unsubstituted Represents a saturated heterocyclic group, a substituted or unsubstituted acyl group, a halogen atom, a nitro group, or a group represented by the formula: one OR 5a , one NR 5a R 5b or one SR 5a (R 5a and R 5a 5b each independently represents a hydrogen
- R 6 is a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted cycle alkyl group, a substituted or unsubstituted cycle group Represents an alkylalkyl group, a substituted or unsubstituted arylalkyl group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted saturated heterocyclic group, or a substituted or unsubstituted acryl group.
- a prodrug thereof, or a pharmaceutically acceptable salt thereof, comprising a poly (ADP-ribose) polymerase inhibitor comprising a poly (ADP-ribose) polymerase inhibitor.
- [4] [1] The compound of the general formula (1) or a prodrug thereof or a pharmaceutically acceptable salt thereof according to [1], wherein ischemic injury, stroke, sequela after stroke, cerebral edema, neurodegenerative disease, Parkinson's disease, Alzheimer's disease, Huntington's chorea, brain contusion, head trauma, spinal cord injury, diabetes, ischemic heart disease, myocardial infarction, myocardial ischemia reperfusion injury, angina, arrhythmia, arthritis, rheumatoid arthritis, Inflammatory bowel disease, sepsis, cancer, or skin aging Use in the manufacture of therapeutic agents.
- a compound of the general formula (1) according to (1) or a prodrug thereof or a pharmaceutically acceptable salt thereof administering to a patient in need of treatment a compound of the general formula (1) according to (1) or a prodrug thereof or a pharmaceutically acceptable salt thereof, cerebral ischemic injury, stroke, Sequelae after stroke, cerebral edema, neurodegenerative disease, Parkinson's disease, Alcheimer's disease, Huntington's chorea, cerebral contusion, head trauma, spinal injury, diabetes, ischemic heart disease, myocardial infarction, myocardial ischemia reperfusion injury How to treat angina, arrhythmia, arthritis, rheumatoid arthritis, inflammatory bowel disease, sepsis, cancer, or skin aging.
- R 7 is a hydrogen atom, a substituted or unsubstituted alkyl group, Or unsubstituted alkenyl group, substituted or unsubstituted alkynyl group, substituted or unsubstituted cycloalkyl group, substituted Or an unsubstituted cycloalkyl group, a substituted or unsubstituted arylalkyl group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted saturated heterocyclic group, or a substituted or unsubstituted acyl group
- R 8 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted
- R ⁇ R 2 , R 3 and R 4 each independently represent a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted Cycloalkyl group, substituted or unsubstituted cycloalkylalkyl group, substituted or unsubstituted arylalkyl group, substituted or unsubstituted aromatic group, substituted or unsubstituted saturated heterocyclic group, substituted or unsubstituted acyl group Represents a group, a nitrogen atom, a nitro group, or a group represented by the formula: _OR la , one NR la R lb or one SR la (R la and R lb are each independently a hydrogen atom or Or an unsubstituted alkyl group).
- R 5 is a substituent on the piperazine ring, which may be absent or one or more, the same or different, and may be a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted Or an unsubstituted alkynyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkylalkyl group, a substituted or unsubstituted arylalkyl group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted Represents a saturated heterocyclic group, a substituted or unsubstituted acyl group, a halogen atom, a nitro group, or a group represented by the formula: —OR 5a , one NR 5a R 5b or one SR 5a (R 5a and R 5b Each independently represents a hydrogen
- R 6 is a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkyl Represents an alkyl group, a substituted or unsubstituted arylalkyl group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted saturated heterocyclic group, or a substituted or unsubstituted acyl group.
- [12] A drug containing the compound according to any one of [7] to [11], or a prodrug thereof, or a pharmaceutically acceptable salt thereof.
- the medical device of [12] which is a poly (ADP-ribose) polymerase inhibitor;
- the pharmaceutical according to [13] which is a therapeutic agent for myocardial infarction, myocardial ischemia-reperfusion injury, angina, arrhythmia, arthritis, rheumatoid arthritis, inflammatory bowel disease, sepsis, cancer, or skin aging.
- [17] a patient comprising administering a compound according to any one of [7] to [11] or a prodrug thereof or a pharmaceutically acceptable salt thereof to a patient in need of treatment; For inhibiting poly (AD P-ribose) polymerase in Escherichia coli.
- a brain disease comprising administering to a patient in need of treatment a compound according to any one of [7] to [11] or a prodrug thereof or a pharmaceutically acceptable salt thereof.
- a compound represented by the general formula (1), a prodrug thereof, or a pharmaceutically acceptable salt thereof is abbreviated as a compound of the present invention as necessary.
- Various groups in the present invention will be described below. Unless otherwise specified, the following description also applies to the case where each of the fundamentals is a part of the basics. Examples of the alkyl group include straight-chain or branched groups such as methyl, ethyl, propyl, 2-propyl, butyl, 2-butyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, hexyl, heptyl, and octyl. Alkyl groups with 8 or less carbon atoms are mentioned.
- alkenyl group examples include alkenyl groups having 6 or less carbon atoms such as vinyl, aryl, propenyl, 2-propenyl, butenyl, pentenyl and hexenyl.
- alkynyl group examples include alkynyl groups having 6 or less carbon atoms such as ethynyl, propargyl, butynyl and pentynyl.
- cycloalkyl group examples include 3- to 8-membered cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
- Examples of the cycloalkenyl group include a 3- to 8-membered double ring such as 1-cyclopentenyl, 2-cyclopentenyl, 3-cyclopentenyl, 1-cyclohexenyl, 2-cyclohexenyl, and 3-cyclohexenyl. Examples thereof include a cycloalkenyl group having one bond.
- Examples of the cycloalkylalkyl group include a group in which the above-mentioned alkyl group is substituted by the above-mentioned cycloalkyl group.
- the aromatic group includes an aryl group and a heteroaryl group.
- Examples of the aryl group include aryl groups having 10 or less carbon atoms, such as a phenyl group and a naphthyl group.
- Examples of the heteroaryl group include a 5- to 6-membered monocyclic group containing 1 to 2 nitrogen atoms, and a 5- to 6-membered monocyclic group containing 1 to 2 nitrogen atoms and one oxygen atom or one sulfur atom.
- a group of the formula a 5-membered monocyclic group containing one oxygen atom or one sulfur atom, a bicyclic group containing 1 to 4 nitrogen atoms and fused with a 6-membered ring and a 5- or 6-membered ring
- Specific examples thereof include, for example, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-chenyl, 3-cheninole, 3-oxaziazolinolene, 2- ⁇ midazolyl, 2 —Thiazolinole, 3- ⁇ sothiazolinole, 2-oxazorifre, 3-isoxazolyl, 2-furyl, 3-furyl, 3-pyrrolyl, 2-quinolinole, 8-quinolinyl, 2-quinazolinyl, 8-purinyl, 1-phthalazinyl, etc.
- halogen atom examples include iodine, fluorine, chlorine and bromine atoms.
- arylalkyl group include an alkyl group substituted by the aryl group.
- saturated heterocyclic group examples include a 5- to 8-membered ring group having one nitrogen atom such as 1-piperidinyl and 1-pyrrolidinyl, and a 6- to 8-membered group having two nitrogen atoms such as 1-piperazinyl. And a 6- to 8-membered ring group having one nitrogen atom and one oxygen atom such as morpholino.
- Examples of the substituent for the saturated heterocyclic group and the saturated heterocyclic carbonyl group include a substituent on a carbon atom such as a hydroxyl group, a carboxyl group, a halogen atom, an alkoxycarbonyl group, and the like; an alkyl group as a substituent on a nitrogen atom; Alkoxycarbonyl group and the like can be mentioned.
- acryl group examples include a formyl group, for example, an alkanoyl group having 2 to 6 carbon atoms such as acetyl and propanol, and a carbon atom having 4 to 7 carbon atoms such as cyclopropanecarbonyl, cyclobutanecarbonyl, cyclopentanecarbonyl and cyclohexanecarbonyl.
- a formyl group for example, an alkanoyl group having 2 to 6 carbon atoms such as acetyl and propanol
- a carbon atom having 4 to 7 carbon atoms such as cyclopropanecarbonyl, cyclobutanecarbonyl, cyclopentanecarbonyl and cyclohexanecarbonyl.
- a cycloalkenecarbonyl group having 4 to 7 carbon atoms such as cyclopentenecarbonyl and cyclohexenecarbonyl; for example, an arylo group having 7 to 11 carbon atoms such as benzoyl, toluoyl and naphthoyl, for example Nitrogen atom, oxygen atom, sulfur source such as 2-piperidinecarbonyl and 3-morpholinecarbonyl
- a saturated heterocyclic carbonyl group having a 5- or 6-membered saturated hetero ring containing 1 or 2 heteroatoms selected from the group consisting of 2-furoyl, 3-furoyl, 2-tenoyl, 3-tenoyl, and nicotinol
- Alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, alkanoyl, cycloalkanecarbonyl, cycloalkenecarbonyl, and arylalkyl groups may have one or the same substituent (s).
- the substituent may be, for example, a nitrogen atom, a cyano group, a phenoxy group, a benzyloxy group, a trifluoromethyl group, a hydroxyl group, a lower alkoxy group, a lower alkanoyloxy group, Amino group, mono-lower alkylamino group, di-lower alkylamino group, carbamoyl group, lower alkylaminocarbonyl group, di-lower alkylaminocarbonyl group, lower alkoxycarbonylamino group, carboxyl group, lower alkoxycarbonyl group, lower Archi Examples include a ruthio group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, a lower alkanoylamino group, a lower alkylsulfonamide group, a tri-lower alkylsilyl group, a phthalimide group, a heteroaryl group, and
- the substituents on the aryl group of the aromatic group, arylo group and heteroaromatic acyl group, and the aryl portion of the arylalkyl group may be one or the same or different, and may be, for example, a nitrogen atom, a cyano atom.
- Lower means that the alkyl moiety of the substituent is a lower alkyl group.
- Examples of such a lower alkyl group include groups having 4 or less carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.
- R 6a represents a group other than a hydrogen atom in the definition of R 6 above
- the compound represented by the general formula (2) is a known compound, or can be synthesized from a known compound by combining known methods. For example, it can be obtained by the method described in Cem. Pharm. Bull. (1972), 20 (7), 1513-1521 and the like.
- Step (a) is a reaction in which a compound represented by the formula (2) is reacted with an N_-substituted piperazine represented by the formula (3) to give a compound represented by the formula (4). It can be carried out by heating at 80 ° C to 220 ° C, preferably 100 ° C to 200 ° C, usually in a solvent such as ethylene dalicol or dioxane or in the absence of a solvent (for example, Acta Chim. Acad. Sci.
- Step (b) is a reaction in which a compound represented by the formula (2) is reacted with a piperazine represented by the formula (5) to give a compound represented by the formula (6). This can be done in the same way as a). At this time, the piperazine represented by the formula (5) has two secondary amide moieties, and thus is preferably used in an excess amount.
- Step (c) is a reaction in which a group represented by the formula: _R 6a is introduced into the compound represented by the formula (6) to give a compound represented by the formula (4).
- Various derivatives can be produced using a general method commonly used in the production of such derivatives.
- an alkyl group for example, an alkyl group or a halogenated alkyl group (chlorine, bromine or iodine is used as a halogen atom) in the presence of a base such as potassium carbonate, for example, acetonitrile or dimethylformamide It can be produced in a solvent, for example, at 0 ° C. at the boiling point of the solvent.
- a ketone or an aldehyde can be used to prepare a reducing agent such as sodium cyanoborohydride in a solvent such as methanol.
- the compound is produced in the presence of hydrogen chloride, acetic acid, or the like, for example, at 0 ° C. and at the boiling point of the solvent.
- an acyl group when introduced, it can be produced, for example, using an acid halide in the presence of a base such as triethylamine in a solvent such as methylene chloride or tetrahydrofuran, for example, at 0 ° C at the boiling point of the solvent.
- a carboxylic acid may be used, for example, dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIPC), 1-ethyl-3- (3-dimethylaminopropyl) -carbodi Imido (WSC), benzotriazolyl-1-yl lute tris (dimethinoleamino) phosphonium.hexafluorophosphoride salt (BOP), diphenylphosphonyl azide (DPPA), N, N-carbonyldiimidazole (Angew. Chem. Int. In the presence of a condensing agent such as Ed. Engl., Vol.
- Tetrahydrofuran, 1,4-dioxane and other ether solvents, dichloromethane, chloroform, halogenated hydrocarbon solvents such as 1,2-dichloroethane, dimethyl Formamide, amide Solvent such as dimethyl ⁇ Seto amides can be prepared in a basic solvent or a mixed solvent thereof, such as pyridine.
- the reaction may be carried out in a conventional manner, for example, by reacting a compound represented by the formula: R 7 X 3 (X 3 represents a halogen atom such as bromine) in the presence of a base such as potassium carbonate in the presence of DMF or the like. Reaction in a solvent at room temperature to 100 ° C., preferably at about 70 ° C. (Chem. Pharm.
- the starting compound for each reaction has a group active in the reaction, such as a hydroxyl group, an amino group or a carboxylic acid group
- these groups may be added to an appropriate protecting group if necessary.
- the target compound can be obtained by removing the protecting group after performing each reaction or after performing several reactions.
- a protecting group for protecting a hydroxyl group, an amino group, a carboxyl group, or the like an ordinary protecting group used in the field of synthetic organic chemistry may be used, and such a protecting group may be introduced and removed according to a usual method. (Eg, the method described in Protective Groups in Organic Synthesis, JOHN WILLEY & SONS, 1991).
- a protecting group for a hydroxyl group includes a methoxymethyl group and a tetrahydroviranyl group
- a protecting group for an amino group includes a tert-butyloxycarbonyl group.
- Such a hydroxyl-protecting group can be removed, for example, by reacting in a solvent such as aqueous methanol, aqueous ethanol, or aqueous tetrahydrofuran in the presence of an acid such as a base, sulfuric acid, or acetic acid.
- the protecting group can be removed, for example, by reacting in a solvent such as hydrated tetrahydrofuran, methylene chloride, chloroform, or hydrated methanol in the presence of an acid such as hydrochloric acid or trifluoroacetic acid.
- a solvent such as hydrated tetrahydrofuran, methylene chloride, chloroform, or hydrated methanol
- an acid such as hydrochloric acid or trifluoroacetic acid.
- the form of protection includes, for example, tert-butyl ester, orthoester, acid amide and the like.
- tert-butyl ester such a protective group is removed, for example, by reacting in the presence of hydrochloric acid in a solvent containing water, and in the case of the ortho ester, for example, aqueous methanol, water-containing tetrahydrofuran,
- the treatment is carried out by treating with an acid in a solvent such as water-containing 1,2-dimethoxyethane, followed by treatment with an alkali such as sodium hydroxide.
- an acid amide for example, the presence of an acid such as hydrochloric acid or sulfuric acid
- the reaction can be performed in a solvent such as water, hydrated methanol, or hydrated tetrahydrofuran.
- the compounds represented by the formula (1) include those having an optically asymmetric center, and therefore, they may be in a racemic form or in an optically active form when an optically active starting material is used. Obtainable. If necessary, the obtained racemate can be physically or optically resolved into its optical antipodes by known methods. Preferably, a diastereomer is formed from a racemate by a reaction using an optically active resolving agent. Different diastereomers can be separated by known methods such as fractional crystallization. “Prodrugs” include those that are readily hydrolyzed in vivo and reproduce the compound of the formula (1). For example, in the case of a compound having a carboxyl group, the carboxyl group becomes an alkoxycarbonyl group.
- an alkylthiocarbonyl group or a compound that has become an alkylaminocarbonyl group.
- a compound having an amino group a compound in which the amino group is substituted with an alkanoyl group to become an alkanoylamino group, a compound in which the amino group is substituted with an alkoxycarbonyl group and becomes an alkoxycarbonylamino group, and acyloxymethyl
- acyloxymethyl A compound that has become an amino group or a compound that has become hydroxylamine.
- a compound having a hydroxyl group a compound in which the hydroxyl group is substituted with the above-mentioned acyl group to form an acyloxy group, a compound which becomes a phosphoric ester, or a compound which becomes an acyloxymethyloxy group is used.
- the alkyl moiety of the group used in these prodrugs include the above-mentioned alkyl groups, and the alkyl group may be substituted (for example, by an alkoxy group having 1 to 6 carbon atoms).
- Preferable examples include, for example, a compound in which a carboxyl group is an alkoxycarbonyl group, such as methoxycarbonyl, ethoxycarbinole, and other lower (for example, having 1 to 6 carbon atoms) alkoxyl carbonyl, methoxymethoxycarbonyl, and ethoxycarbonyl.
- Lower (for example, having 1 to 6 carbon atoms) alkoxycarbonyl substituted by an alkoxy group such as methoxycarbonyl, 2-methoxyethoxycarbonyl, 2-methoxyethoxymethoxycarbonyl, and pivaloyloxymethoxycarbonyl.
- the compound represented by the formula (1) or a prodrug thereof can be converted into a pharmaceutically acceptable salt, if necessary.
- salts include salts with mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid; formic acid, acetic acid, fumaric acid, maleic acid, oxalic acid, citric acid, malic acid, tartaric acid, and aspartic acid.
- Salts with organic carboxylic acids such as glutamic acid and sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, hydroxybenzenesulfonic acid and dihydroxybenzenesulfonic acid Salt; and
- alkali metal salts such as sodium salt and potassium salt
- alkaline earth metal salts such as calcium salt and magnesium salt
- ammonium salt triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, dicyclohexylamine salt, N, N and salts with dibenzylethylenediamine.
- the compound represented by the formula (1) or a prodrug thereof or a pharmaceutically acceptable salt thereof may be an anhydride, hydrate or solvate thereof.
- the compounds of the present invention can be administered orally or parenterally when using them as medicaments.
- a commonly used dosage form for example, a powder, granule, tablet, capsule, syrup, suspension or the like, or, for example, a solution, emulsion, or suspension thereof.
- the above-mentioned suitable dosage form can be produced, for example, by mixing the compound of the present invention with an acceptable usual carrier, excipient, binder, stabilizer, or diluent.
- an acceptable buffer, solubilizing agent and isotonic agent can be added in parallel.
- the dosage and number of administrations vary depending on, for example, the target disease, symptoms, age, body weight, and dosage form, but are usually 0.1 to 2000 mg, preferably 1 to 200 mg once a day for an adult. It can be administered in several divided doses (eg, 2-4 times).
- NAD Nacalai Tesque
- -Glass fiber filter for 96mm plate Printed filter matt B (double thickness, 90X 120 thighs) (PerkinElmer, In (USA))
- Solid scintillator sheet MeltiLex (TM) A (73X 109 mm, ⁇ 4 g count) (PerkinElmer, Inc. (USA))
- a buffer (50% Tris-HCl (pH 8.0) / 25 mM MgCl 2 aqueous solution) was used for the preparation of each solution.
- the reaction was stopped by the addition of 2 ⁇ M of benzamide at 9 ⁇ 1 / Pell (2 after addition), and the ⁇ in the reaction mixture was reduced with a cell harvester (HARVESTER 96 (registered trademark), T0MTEC Inc. (USA) ) Collected on glass fiber filter for plate and filter.
- the glass fiber filter was passed through 80% ethanol immediately before recovery of PAP. After PARP recovery, each well of the plate was washed four times with 80% ethanol, and the washing solution was also passed through the glass fiber filter. Heat the glass fiber filter in a microwave oven for 3 to 4 minutes to dry, place two solid scintillator sheets on top of each other and place in a sample bag. And sealed.
- the compound of the present invention has a PARP inhibitory action, and thus, for example, a disease caused by enhanced PARP activity, for example, cerebral ischemic injury, neurodegenerative disease, cerebral contusion, head injury, spinal injury, diabetes, ischemic heart Disease, organ damage due to ischemia or ischemia reperfusion, inflammation, inflammatory bowel disease, cancer, cachexia, renal disorder, osteoporosis, acute and chronic pain, sepsis, skeletal muscle degeneration, muscular dystrophy, skin aging, immunity It can be used as a therapeutic agent for system aging, AIDS, changes in gene expression of senescent cells, etc.
- a disease caused by enhanced PARP activity for example, cerebral ischemic injury, neurodegenerative disease, cerebral contusion, head injury, spinal injury, diabetes, ischemic heart Disease, organ damage due to ischemia or ischemia reperfusion, inflammation, inflammatory bowel disease, cancer, cachexia, renal disorder, osteoporosis, acute and chronic pain, sepsis, skeletal muscle degeneration, muscular dys
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001248748A AU2001248748A1 (en) | 2000-04-18 | 2001-04-10 | Substituted piperazine compounds |
JP2001576785A JPWO2001079184A1 (ja) | 2000-04-18 | 2001-04-10 | 置換ピペラジン類 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000116578 | 2000-04-18 | ||
JP2000-116578 | 2000-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001079184A1 true WO2001079184A1 (fr) | 2001-10-25 |
Family
ID=18628025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/003107 WO2001079184A1 (fr) | 2000-04-18 | 2001-04-10 | Composes de piperazine substitues |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2001079184A1 (ja) |
AU (1) | AU2001248748A1 (ja) |
WO (1) | WO2001079184A1 (ja) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004048339A1 (ja) | 2002-11-22 | 2004-06-10 | Mitsubishi Pharma Corporation | イソキノリン化合物及びその医薬用途 |
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
JP2007504238A (ja) * | 2003-09-04 | 2007-03-01 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ポリ(adp−リボース)ポリメラーゼ(parp)の阻害剤としての置換インドール |
US7196085B2 (en) | 2002-04-30 | 2007-03-27 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7220759B2 (en) | 2002-10-01 | 2007-05-22 | Mitsubishi Pharma Corporation | Isoquinoline compound and pharmaceutical use thereof |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7470688B2 (en) | 2005-10-19 | 2008-12-30 | Maybridge Limited | Phthalazinone derivatives |
US7692006B2 (en) | 2006-10-17 | 2010-04-06 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
EP2305221A1 (en) | 2003-12-01 | 2011-04-06 | Kudos Pharmaceuticals Limited | Dna damage repair inhibitors for treatment of cancer |
WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
US7981890B2 (en) | 2007-09-14 | 2011-07-19 | Astrazeneca Ab | Phthalazinone derivatives |
US8129380B2 (en) | 2008-01-23 | 2012-03-06 | Astrazeneca Ab | Phthalazinone derivatives |
US8475842B2 (en) | 2008-10-07 | 2013-07-02 | Astrazeneca Ab | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
US8912187B2 (en) | 2003-03-12 | 2014-12-16 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
WO2018197461A1 (en) | 2017-04-28 | 2018-11-01 | Akribes Biomedical Gmbh | A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing |
WO2019175132A1 (en) | 2018-03-13 | 2019-09-19 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
EP3594343A1 (en) | 2015-07-23 | 2020-01-15 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
US10799501B2 (en) | 2015-11-05 | 2020-10-13 | King's College Hospital Nhs Foundation Trust | Combination of an inhibitor of PARP with an inhibitor of GSK-3 or DOT1L |
WO2021048235A1 (en) | 2019-09-10 | 2021-03-18 | The Francis Crick Institute Limited | Treatment of hr deficient cancer |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994021631A1 (en) * | 1993-03-22 | 1994-09-29 | Nippon Kayaku Kabushiki Kaisha | Chroman derivative and use thereof |
-
2001
- 2001-04-10 WO PCT/JP2001/003107 patent/WO2001079184A1/ja active Application Filing
- 2001-04-10 AU AU2001248748A patent/AU2001248748A1/en not_active Abandoned
- 2001-04-10 JP JP2001576785A patent/JPWO2001079184A1/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994021631A1 (en) * | 1993-03-22 | 1994-09-29 | Nippon Kayaku Kabushiki Kaisha | Chroman derivative and use thereof |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7196085B2 (en) | 2002-04-30 | 2007-03-27 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7459465B2 (en) | 2002-10-01 | 2008-12-02 | Mitsubishi Tanabe Pharma Corporation | Isoquinoline compound and pharmaceutical use thereof |
US7812178B2 (en) | 2002-10-01 | 2010-10-12 | Mitsubishi Tanabe Pharma Corporation | Isoquinoline compound and pharmaceutical use thereof |
US7220759B2 (en) | 2002-10-01 | 2007-05-22 | Mitsubishi Pharma Corporation | Isoquinoline compound and pharmaceutical use thereof |
US7501412B2 (en) | 2002-11-22 | 2009-03-10 | Mitsubishi Tanabe Pharma Corporation | Isoquinoline compounds and medicinal use thereof |
WO2004048339A1 (ja) | 2002-11-22 | 2004-06-10 | Mitsubishi Pharma Corporation | イソキノリン化合物及びその医薬用途 |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US8912187B2 (en) | 2003-03-12 | 2014-12-16 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7662818B2 (en) | 2003-03-12 | 2010-02-16 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US10449192B2 (en) | 2003-03-12 | 2019-10-22 | Kudo Pharmaceuticals Limited | Phthalazinone derivatives |
US11160803B2 (en) | 2003-03-12 | 2021-11-02 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US9566276B2 (en) | 2003-03-12 | 2017-02-14 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US9169235B2 (en) | 2003-03-12 | 2015-10-27 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
JP2007504238A (ja) * | 2003-09-04 | 2007-03-01 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ポリ(adp−リボース)ポリメラーゼ(parp)の阻害剤としての置換インドール |
EP2305221A1 (en) | 2003-12-01 | 2011-04-06 | Kudos Pharmaceuticals Limited | Dna damage repair inhibitors for treatment of cancer |
US7470688B2 (en) | 2005-10-19 | 2008-12-30 | Maybridge Limited | Phthalazinone derivatives |
US7902193B2 (en) | 2005-10-19 | 2011-03-08 | Maybridge Limited | Phthalazinone derivatives |
US7692006B2 (en) | 2006-10-17 | 2010-04-06 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7981890B2 (en) | 2007-09-14 | 2011-07-19 | Astrazeneca Ab | Phthalazinone derivatives |
US8129380B2 (en) | 2008-01-23 | 2012-03-06 | Astrazeneca Ab | Phthalazinone derivatives |
US8475842B2 (en) | 2008-10-07 | 2013-07-02 | Astrazeneca Ab | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
US11633396B2 (en) | 2008-10-07 | 2023-04-25 | Kudos Pharmaceuticals Limited | Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one |
WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
EP3594343A1 (en) | 2015-07-23 | 2020-01-15 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
US10799501B2 (en) | 2015-11-05 | 2020-10-13 | King's College Hospital Nhs Foundation Trust | Combination of an inhibitor of PARP with an inhibitor of GSK-3 or DOT1L |
WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
WO2018197461A1 (en) | 2017-04-28 | 2018-11-01 | Akribes Biomedical Gmbh | A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing |
WO2019175132A1 (en) | 2018-03-13 | 2019-09-19 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
WO2021048235A1 (en) | 2019-09-10 | 2021-03-18 | The Francis Crick Institute Limited | Treatment of hr deficient cancer |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Also Published As
Publication number | Publication date |
---|---|
JPWO2001079184A1 (ja) | 2004-03-18 |
AU2001248748A1 (en) | 2001-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001079184A1 (fr) | Composes de piperazine substitues | |
WO2020259432A1 (zh) | Kras-g12c抑制剂 | |
CN108349981B (zh) | 新型的吡唑并[3,4-d]嘧啶化合物或其盐 | |
CN113286794B (zh) | Kras突变蛋白抑制剂 | |
TW202140461A (zh) | Ras抑制劑及其使用方法 | |
CN112552295A (zh) | Kras突变蛋白抑制剂 | |
CN104884454A (zh) | 用作IL-12、IL-23和/或IFNα应答调节剂的酰胺取代的杂环化合物 | |
EP3812385B1 (en) | Tartrate of selective cdk9 inhibitor and crystal form thereof | |
CN111393415B (zh) | 一种杂芳腈类化合物及其应用 | |
CN110194770A (zh) | 肽酰精氨酸脱亚胺酶抑制剂及其用途 | |
JP2021501179A (ja) | キナーゼ阻害剤としてのアミノイミダゾピリダジン | |
JP2001302515A (ja) | ポリ(adp−リボース)ポリメラーゼ阻害剤 | |
KR20150138847A (ko) | Perk 저해제로서의 신규한 n―(2,3―디히드로―1h―피롤로[2,3―b]피리딘―5―일)―4―퀴나졸린아민 및 n―(2,3―디히드로―1h―인돌―5―일)―4―퀴나졸린아민 유도체 | |
WO2017088723A1 (zh) | 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途 | |
CN112300153A (zh) | 一种杂环化合物、药物组合物和用途 | |
JP2022500418A (ja) | 受容体相互作用タンパク質キナーゼ1阻害剤(ripk1)としての1h−インダゾールカルボキサミド | |
CN117561244A (zh) | 异吲哚啉酮类化合物及其用途 | |
WO2018001332A1 (zh) | 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途 | |
JP7338896B2 (ja) | Mdm2阻害剤、その調製方法、医薬組成物および応用 | |
WO2001079206A1 (fr) | Quinazolinediones tricycliques | |
WO2020187292A1 (zh) | 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用 | |
CN113527311B (zh) | Fgfr4抑制剂、组合物及其在药物制备中的用途 | |
JP6834057B2 (ja) | 糖尿病の治療のためのpde1阻害剤としての[1,2,4]トリアゾロ誘導体 | |
CN111247143B (zh) | 可用作蛋白激酶抑制剂的吡啶并喹唑啉衍生物 | |
EP2787998B1 (en) | Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 576785 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase |